Phaseline

Companies › Ascendis Pharma Oncology Division

Ascendis Pharma Oncology Division: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TransCon IL-2 β/γ
IL-2 receptor agonist with extended half-life via TransCon technology
IL2Phase 1Advanced Solid TumorAug 2027
TransCon TLR7/8 Agonist
TLR7/8 agonist with extended half-life via TransCon technology
TLR7, TLR8Phase 1Advanced Solid TumorAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05081609TransCon IL-2 β/γPhase 1Advanced Solid TumorOncologyAug 2027
NCT05081609TransCon TLR7/8 AgonistPhase 1Advanced Solid TumorOncologyAug 2027

Targets

IL2 (1) TLR7 (1) TLR8 (1)

Companies with the same targets

Merck KGaA Eikon Therapeutics United Immunity Beeline Medicines HighField Biopharmaceuticals Bolt Biotherapeutics Inimmune Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.